Cyclic Ozone Exposure Induces Gender-Dependent Neuropathology and Memory Decline in an Animal Model of Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is a major cause of dementia in the elderly. Although early-onset (familial) AD is attributed to gene mutations, the cause for late-onset (sporadic) AD, which accounts for 95% of AD cases, is unknown. In this study, we show that exposure of 6-week-old amyloid beta precursor protein (APP)/presenilin (PS1) overexpressing mice, a well-established animal model of AD, and nontransgenic littermates to a cyclic O3 exposure protocol, which mimics environmental exposure episodes, accelerated learning/memory function loss in male APP/PS1 mice but not in female APP/PS1 mice or nontransgenic littermates. Female APP/PS1 mice had higher brain levels of amyloid beta peptide (Aβ42) and Aβ40, compared with male APP/PS1 mice; O3 exposure, however, had no significant effect on brain Aβ load in either male or female mice. Our results further show that male APP/PS1 mice had lower levels of antioxidants (glutathione and ascorbate) and experienced augmented induction of NADPH oxidases, lipid peroxidation, and neuronal apoptosis upon O3 exposure, compared with female APP/PS1 mice. No significant effect of O3 on any of these parameters was detected in nontransgenic littermates. In vitro studies further show that 4-hydroxynonenal, a lipid peroxidation product which was increased in the plasma and cortex/hippocampus of O3-exposed male APP/PS1 mice, induced neuroblastoma cell apoptosis. Together, the results suggest that O3 exposure per se may not cause AD but can synergize with genetic risk factors to accelerate the pathophysiology of AD in genetically predisposed populations. The results also suggest that males may be more sensitive to O3-induced neuropathophysiology than females due to lower levels of antioxidants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
Clinical epidemiology of Alzheimer’s disease: assessing sex and gender differences
Mielke, M., Vemuri, P., & Rocca, W. (2014) · Clinical Epidemiology · doi:10.2147/clep.s37929 · Cited by 1,021
The incidence of dementia: A meta-analysis
Jorm, A. F., & Jolley, D. (1998) · Neurology · doi:10.1212/wnl.51.3.728 · Cited by 903
The amyloid hypothesis for Alzheimer’s disease: A critical reappraisal
Hardy, J. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06181.x · Cited by 814
Gender differences in the incidence of AD and vascular dementia: The EURODEM Studies
Andersen, K., Launer, L. J., Dewey, M. E., Letenneur, L., Ott, A., Copeland, J. R. M., Dartigues, J.-F., Kragh–Sorensen, P., Baldereschi, M., Brayne, C., et al. (1999) · Neurology · doi:10.1212/wnl.53.9.1992 · Cited by 650
Incidence of dementia: does gender make a difference?
Ruitenberg, A., Ott, A., van Swieten, J. C., Hofman, A., & Breteler, M. M. B. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00231-7 · Cited by 467
Jung, C.-R., Lin, Y.-T., & Hwang, B.-F. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-140855 · Cited by 380
Early Environmental Origins of Neurodegenerative Disease in Later Life
Landrigan, P. J., Sonawane, B., Butler, R. N., Trasande, L., Callan, R., & Droller, D. (2005) · Environmental Health Perspectives · doi:10.1289/ehp.7571 · Cited by 357
Role of estrogen receptor alpha and beta expression and signaling on cognitive function during aging
Foster, T. C. (2012) · Hippocampus · doi:10.1002/hipo.20935 · Cited by 231
Sex and gender differences in the causes of dementia: A narrative review
Rocca, W. A., Mielke, M. M., Vemuri, P., & Miller, V. M. (2014) · Maturitas · doi:10.1016/j.maturitas.2014.05.008 · Cited by 186
Gender, cognitive decline, and risk of AD in older persons
Barnes, L. L., Wilson, R. S., Schneider, J. A., Bienias, J. L., Evans, D. A., & Bennett, D. A. (2003) · Neurology · doi:10.1212/01.wnl.0000065892.67099.2a · Cited by 173
Pulmonary ozone exposure induces vascular dysfunction, mitochondrial damage, and atherogenesis
Chuang, G. C., Yang, Z., Westbrook, D. G., Pompilius, M., Ballinger, C. A., White, C. R., Krzywanski, D. M., Postlethwait, E. M., & Ballinger, S. W. (2009) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00102.2009 · Cited by 145
Antiamyloid Therapy for Alzheimer's Disease — Are We on the Right Road?
Karran, E., & Hardy, J. (2014) · New England Journal of Medicine · doi:10.1056/nejme1313943 · Cited by 126
Effects of ambient ozone exposure on mail carriers’ peak expiratory flow rates
Chan, C.-C., & Wu, T.-H. (2005) · Environmental Health Perspectives · doi:10.1289/ehp.7636 · Cited by 45
Cited by
Air Pollution and Alzheimer’s Disease: A Systematic Review and Meta-Analysis
Fu, P., & Yung, K. K. L. (2020) · Journal of Alzheimer's Disease · doi:10.3233/jad-200483 · Cited by 146
Greve, H. J., Dunbar, A. L., Lombo, C. G., Ahmed, C., Thang, M., Messenger, E. J., Mumaw, C. L., Johnson, J. A., Kodavanti, U. P., Oblak, A. L., et al. (2023) · Brain · doi:10.1093/brain/awac113 · Cited by 82
Croze, M. L., & Zimmer, L. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170857 · Cited by 78
Metadata
- Authors
- Akhter, H., Ballinger, C., Liu, N., van Groen, T., Postlethwait, E. M., & Liu, R.-M.
- Venue
- Toxicological Sciences
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-06-26
- Volume
- 147
- Issue
- 1
- Pages
- 222-234
- ISSN
- 1096-0929 (ISSN-L)
- 1096-6080
- OpenAlex
- W2299525597
- Cited by
- 37
- References
- 15
- FWCI
- 1.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.